SOFIE
@sofiebio
We are dedicated to improving patient outcomes by developing, supplying and delivering molecular diagnostics and therapeutics (theranostics).
In January, we launched our iPREDICT clinical trial globally in the US, Australia, and Europe.  We are proud to announce the first patient dosed in Australia. Read more here: imaginab.com/news-events/ne… #Australiabiotech #immunotherapy #immunooncology #clinicaltrials
                                            Very excited to test the ability of a novel molecular imaging agent targeting fibroblast activated protein (FAP) to pick up pancreatic cancer!” @sofie @elcinzan @nyulangone @Perlmutter_CC #imagingpancreaticcancer prnewswire.com/news-releases/…
Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug lecanemab slowed the disease, becoming the first medicine to clearly blunt the progression of the most common type of dementia in a final-phase trial $BIIB
Read the FDA's reasoning and remember that @NCCN and @SNM_MI guidelines support the use of other validated and FDA-approved imaging probes for PLUVICTO treatment stratification. ow.ly/i7uQ50JSg9o #PrecisionMedicine #NucMed #ProstateCancer
This is your last week to submit an abstract for WMIC! Submit by July 15th, 2022. Present your science in Miami and don't forget to book your hotel: wmis.org/wmic1/
                                            Current Issue: Fibrous Dysplasia Mimicking Skeletal Metastasis on 68Ga-FAPI PET Imaging dlvr.it/STN0Dh
                                            FAP session at Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting attracts packed audience sofie.com/2022/06/22/fap…
Thanks @SNM_MI for the 2022 Alavi-Mandell award for this @JournalofNucMed publication. Recognition goes to all authors. #PSMA #ProstateCancer #nuclearmedicine snmmi.org/AboutSNMMI/Con…
How perfect. Dr Gambhir would be proud.
Andrei Iagaru, MD, FACNM, has been named as the first recipient of the SNMMI Sam Gambhir Trailblazer Award. Congratulations on this honor! #SNMMI22 #NuclearMedicine
                                                                            Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer dlvr.it/SRC7Rq
O. Sartor discusses the role of PSMA PET/CT for selecting patients for radioligand therapy. Thoughts? Please comment! ow.ly/aIhI50Jk05n #MedicalImaging #PETCT #ProstateCancer @sartor_oliver
Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond @asco Education Book #ASCO22 ascopubs.org/doi/full/10.12… @DrAGafita @LouiseKostos @CalaisJeremie @pros_tic
                                            
                                            
                                            
                                            We invite all WMIC 2022 attendees to fill out our pre-conference survey! ✨We want your input and feedback on WIMIN events you'd like to see at the upcoming WMIC conference. Fill out a survey & have a chance to win a $25 Amazon gift cards✨ surveymonkey.ca/r/YCRVYJT @WMISWMIC
                                            What are the three pillars of survival for a drug in development? Find out how the pioneering ImmunoPET technology works. @ImaginAbInc speaks to @OGConferences at our In Vivo imaging discussion group. #OGcollab oxfordglobal.co.uk/resources/bett…
Impressive and inspiring talk by Jason Lewis @LewisLabMSKCC at the @CRUK_BI today. Jason gave us an excellent vision of the future for #PET imaging and #theranostics. Phenomenal data.
                                            Also great to see 177Lu-PSMA-617 added to the NCCN guidelines. As expected post-chemo and post-ARTT. Nice speedy updates by the NCCN panel. #PSMARLT bit.ly/3LkJV2v
                                            Glad to see that the NCCN agrees that either 18F-DCFPyL or 68Ga-PSMA-11 should be used for selection of patients for 177Lu-PSMA-617 radioligand therapy. Hopefully we can put this issue to rest as soon as possible! #PSMAPET - bit.ly/3LkJV2v
                                            Our goal
To attract and retain the best people, we must redesign jobs around a simple but powerful concept: love for the content of the work itself. hbr.org/2022/05/design…
hbr.org
Designing Work That People Love
Resignations are at an all-time high, and companies desperate to fill vacancies are trying everything from pay raises to trendy perks. But those interventions are falling short, because the real...
Look forward to seeing you all @WMISWMIC #molecular imaging #science #innovation @UCDavisResearch @LewisLabMSKCC @UCDavisCMGI @juliesut8
REMINDER: WMIC 2022 abstract deadline is next Wednesday, May 4th, 2022. Submit your abstract: ow.ly/bxRb50ISZP6 We can't wait to see you in Miami!
                                                                            United States الاتجاهات
- 1. Cowboys 70.3K posts
 - 2. Nick Smith 17.9K posts
 - 3. #WeTVAlwaysMore2026 1.11M posts
 - 4. Kawhi 4,689 posts
 - 5. Cardinals 31.7K posts
 - 6. #WWERaw 65.9K posts
 - 7. Jonathan Bailey 36.5K posts
 - 8. #LakeShow 3,568 posts
 - 9. Jerry 46.3K posts
 - 10. #River 5,076 posts
 - 11. Kyler 8,893 posts
 - 12. No Luka 3,907 posts
 - 13. Blazers 8,519 posts
 - 14. Valka 5,135 posts
 - 15. Logan Paul 10.9K posts
 - 16. #AllsFair N/A
 - 17. Dalex 2,800 posts
 - 18. Pacers 14.1K posts
 - 19. Jacoby 8,786 posts
 - 20. Constance 3,542 posts
 
Something went wrong.
Something went wrong.